Amicus had said they were doing some preclinical work looking at the possibility of administering their chaperone with ERT (I don't recall which of the three but think either in Fabry or Gaucher). While it would open up a very interesting opportunity this doesn't make a lot of sense to me as wouldn't this imply the replaced enzyme also has the mutation?
The Shire time line may not have changed my comment was from when TKT was a standalone company and they were looking at possible commericialization in 2008 here is a PR after their Phase I/II. http://phx.corporate-ir.net/phoenix.zhtml?c=95926&p=irol-newsArticle&ID=698247&highlight I think initially they had hoped to get approval based on just that one trial (Cerezyme may have needed just 1 trial to go from Ceredase)
Market Data 
Markets 
AI
